PUBLIC HEALTH AND ECONOMIC IMPACT OF PCV21 ON PNEUMOCOCCAL DISEASE IN ADULT NATIONAL IMMUNIZATION PROGRAMME IN DENMARK
Author(s)
Simone Ruth Flindhardt, MSc1, Maja Holm Vinfeldt, MSc1, Guoming Shi, MSc2, Dzhumber Ugrekhelidze, PharmD, PhD3, Zinan Yi, PhD4, Eleana Tsoumani, MSc5, Kwame Owusu-Edusei, PhD4.
1MSD Denmark, Copenhagen, Denmark, 2Amaris Consulting, Barcelona, Spain, 3MSD, Zurich, Switzerland, 4Merck & Co., Inc., Rahway, NJ, USA, 5MSD, Athens, Greece.
1MSD Denmark, Copenhagen, Denmark, 2Amaris Consulting, Barcelona, Spain, 3MSD, Zurich, Switzerland, 4Merck & Co., Inc., Rahway, NJ, USA, 5MSD, Athens, Greece.
OBJECTIVES: This study aimed to assess the potential health and economic impact of PCV21 within an adult National Immunization Program (NIP) in Denmark.
METHODS: A published state-transition Markov model was used. Two strategies were evaluated from a societal perspective: PCV21 or PCV20 with 5% coverage, each compared with current practice (CP): PPSV23 at 5% coverage in the at-risk population and PCV20 at 5% coverage in the high-risk population. Scenario with hypothetical 80% VCR for PCV21 or PCV20 under NIP was also assessed. The model was applied to three age cohorts: 60-100 years, 65-100 years, and 75-100 years. List prices of vaccines were applied.
RESULTS: In conditional reimbursement scenario, at 5% VCR for both PCV21 and CP, PCV21 averted 927 pneumococcal disease (PD) cases, 61 deaths, and cut total costs by DKK 59.22 million in the 60-100-year age cohort. In NIP scenario, PCV21 at 80% coverage compared to CP averted 40,554 pneumococcal disease (PD) cases, 2,601 deaths and decreased total costs of DKK 1.60 billion over the lifetime horizon in the 60-100-year age cohort. In adults aged 65+ and 75+, PCV21 prevented 35,357 and 20,636 PD cases, 2,409 and 1,686 deaths, and reduced total costs by DKK 1.45 billion and DKK 867 million respectively. PCV20 at 80% coverage compared with CP was associated with a reduction in total costs of DKK 879 million, averted 30,199 PD cases, 990 deaths in the 60-100-year cohort. Both cost savings and health impact decreased in both scenarios when vaccination was initiated at older ages (65+ and 75+ years).
CONCLUSIONS: Overall, the 60-100-year program with PCV21 was the most beneficial scenario in comparison to PCV20, yielding the largest cost reductions and public health gains over the lifetime horizon. Across all age cohorts, PCV21 consistently outperformed PCV20, despite the lower acquisition cost of PCV20.
METHODS: A published state-transition Markov model was used. Two strategies were evaluated from a societal perspective: PCV21 or PCV20 with 5% coverage, each compared with current practice (CP): PPSV23 at 5% coverage in the at-risk population and PCV20 at 5% coverage in the high-risk population. Scenario with hypothetical 80% VCR for PCV21 or PCV20 under NIP was also assessed. The model was applied to three age cohorts: 60-100 years, 65-100 years, and 75-100 years. List prices of vaccines were applied.
RESULTS: In conditional reimbursement scenario, at 5% VCR for both PCV21 and CP, PCV21 averted 927 pneumococcal disease (PD) cases, 61 deaths, and cut total costs by DKK 59.22 million in the 60-100-year age cohort. In NIP scenario, PCV21 at 80% coverage compared to CP averted 40,554 pneumococcal disease (PD) cases, 2,601 deaths and decreased total costs of DKK 1.60 billion over the lifetime horizon in the 60-100-year age cohort. In adults aged 65+ and 75+, PCV21 prevented 35,357 and 20,636 PD cases, 2,409 and 1,686 deaths, and reduced total costs by DKK 1.45 billion and DKK 867 million respectively. PCV20 at 80% coverage compared with CP was associated with a reduction in total costs of DKK 879 million, averted 30,199 PD cases, 990 deaths in the 60-100-year cohort. Both cost savings and health impact decreased in both scenarios when vaccination was initiated at older ages (65+ and 75+ years).
CONCLUSIONS: Overall, the 60-100-year program with PCV21 was the most beneficial scenario in comparison to PCV20, yielding the largest cost reductions and public health gains over the lifetime horizon. Across all age cohorts, PCV21 consistently outperformed PCV20, despite the lower acquisition cost of PCV20.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE135
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines